AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 24 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A potential HIV vaccine using a modified vesicular stomatitis virus (VSV)-based vector has shown promise in animal studies, according to researchers in the United States.
"VSV vectors are promising candidates for human AIDS vaccine trials because they propagate to high titers and can be delivered without injection," explained John K. Rose, Yale University School of Medicine, and colleagues in a multicenter study.
Animals inoculated with a VSV-based vaccine displayed a high degree of protection from simian HIV (SHIV) infection, Rose and coauthors reported.
Rhesus monkeys were used to evaluate the efficacy of these vaccines. Priming immunization was achieved with attenuated VSV vectors engineered to express genes coding for the HIV proteins env and gag, with glycoproteins from a variety of VSV serotypes used for boosting, according to the report.
The seven inoculated animals were challenged with the extremely virulent simian HIV 89.6P (SHIV89.6P) strain. Despite acute infection, treated monkeys have maintained extremely low plasma SHIV RNA levels for more than a year after exposure, study data showed.
By contrast, untreated animals exposed to SHIV89.6P ...
Source: HighBeam Research, Vesicular Stomatitis Virus Vector Effective.